PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.56%
Revenue growth of 4.56% while 3141.T is flat. Bruce Berkowitz would check if a small edge can widen further.
2.69%
Gross profit growth of 2.69% while 3141.T is zero. Bruce Berkowitz would see if minimal improvements could expand further.
5.94%
EBIT growth of 5.94% while 3141.T is zero. Bruce Berkowitz would see if small gains can be scaled further.
0.67%
Operating income growth of 0.67% while 3141.T is zero. Bruce Berkowitz would see if this modest edge can become significant.
-4.69%
Negative net income growth while 3141.T stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.70%
Negative EPS growth while 3141.T is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-4.70%
Negative diluted EPS growth while 3141.T is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while 3141.T stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.03%
10Y revenue/share CAGR under 50% of 3141.T's 42.86%. Michael Burry would suspect a lasting competitive disadvantage.
-7.20%
Negative 5Y CAGR while 3141.T stands at 46.93%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-32.91%
Negative 3Y CAGR while 3141.T stands at 24.85%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
24.45%
Below 50% of 3141.T's 74.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
15.10%
Below 50% of 3141.T's 71.33%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-43.23%
Negative 3Y CAGR while 3141.T is 28.27%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
33.35%
Below 50% of 3141.T's 102.23%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-12.89%
Negative 3Y equity/share growth while 3141.T is at 60.59%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 3141.T stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
No Data
No Data available this quarter, please select a different quarter.
-99.40%
Firm’s AR is declining while 3141.T shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.08%
Inventory growth of 0.08% while 3141.T is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
1.93%
Asset growth of 1.93% while 3141.T is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
4.20%
BV/share growth of 4.20% while 3141.T is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-34.68%
We’re deleveraging while 3141.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
82.29%
SG&A growth of 82.29% while 3141.T is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.